AUTOIMMUNE DIABETES (type 1 diabetes; T1D) is a multifaceted metabolic disorder characterized by hyperglycemia, which results in the long-term development of cardiovascular and neuropathic complications. The etiology of T1D is complex, however. Autoimmunity and insulitis are believed to be key aspects of this disease (6, 36) . Islet infiltration of leukocytes, such as CD4 ϩ and CD8 ϩ T cells, are believed to contribute to ␤-cell destruction (4, 16, 43, 45, 47) . Examination of leukocyte adhesion molecules expressed during autoimmune diabetes reveals that lymphocyte function-associated antigen-1 (LFA-1; ␣ L ␤ 2 -antigen), Mac-1 (␣ M ␤ 2 -integrin), ␣ 4 -and ␤ 1 -integrins, and L-selectin may all be involved in development of disease (7, 8, 15, 29, 31, 32) . Consistent with these observations, reports have shown increased ␣ L ␤ 2 -integrin expression on mononuclear cells from T1D patients, which correlated with islet cell autoantibody titers and increased expression of counter-ligand endothelial cell adhesion molecules, such as ICAM-1 (2, 33) . However, the specific molecular mechanisms required for immune cell adhesion to pancreatic islet microvascular endothelium remains unknown.
Recruitment of leukocytes into extravascular tissues occurs through a concerted multistep process involving leukocyte rolling, firm adhesion, and emigration across the vascular endothelium. Leukocyte firm adhesion and transmigration are governed, in part, by the ␤ 2 -integrin family, or CD18 integrins, which consists of four different adhesion proteins: ␣ L ␤ 2 -(LFA-1), ␣ M ␤ 2 -(Mac-1), ␣ X ␤ 2 -(p150/95), and ␣ D ␤ 2 -proteins. Importantly, expression of the ␤ 2 -integrins is limited to leukocytes, indicating their importance for immune responses. Members of the immunoglobulin superfamily serve as the major ligands for the ␤ 2 -integrins, including ICAM-1, -2, and -3, and others (18, 19) . Integrin-mediated cell adhesion is controlled through multiple mechanisms that include alterations in surface density of ligand and changes in receptor affinity and avidity (24, 44) . Several studies have demonstrated that the ␣-chain I domain is important for specific ligand binding and integrin function (5, 42, 51) . The I domain is highly homologous among integrins that contain one, yet specific differences have been noted between the metal ion-dependent adhesion site of the ␣ L -and ␣ M -molecules (9, 27) . These and other differences have been suggested to be functionally important in terms of specific integrin actions, yet the precise biological role of these motifs and possible therapeutic intervention at these sites has not been determined.
Here we examine the specific adhesion molecule requirements involved during leukocyte-islet microvascular endothelial cell interactions using specific cyclic peptide antagonists that are designed to compete with ␣ L -integrin I domain binding to its ligand, combined with a high temporal and spatial resolution in vitro flow chamber model. We report that T cell, but not monocyte, adhesion to islet microvascular endothelium is critically dependent on ␣ L -integrin I domain interaction with ligand even when other adhesion molecules are present (e.g., VCAM-1/VLA-4). We also show that inhibition of ␣ L -integrin I domain function increases the average rolling velocity of T cells by decreasing the number of T cells rolling at velocities Ͻ50 m/s. These data demonstrate that cyclic peptide competition with the ␣ L -integrin I domain for ligand may be useful in attenuating T cell recruitment during autoimmune diabetes. microvascular endothelial cell lines were purchased from American Type Culture Convention (ATCC; Manassas, VA). All cell culture medium materials and recombinant mouse TNF-␣ were purchased from Sigma (St. Louis, MO). Corning cell culture plasticware was purchased from VWR (Suwanee, GA). Anti- Peptide synthesis. Cyclic peptides cLAB.L (cyclo1,12-Pen-ITDGEATDSGC) and cyclic CGFCG control peptide were synthesized by using the solid phase method by Multiple Peptide Systems (San Diego, CA) as previously reported (46, 50) . The crude cLAB.L peptide was purified by preparative HPLC using reversed-phase C-18 column. The pure product was analyzed by NMR and fast atom bombardment mass spectrometry.
Cell culture. Cells were cultured by using ATCC recommended guidelines along with recommended media. WEHI cell lines were grown in suspension in T-75 flasks, whereas adherent MS1 endothelial cell cultures were grown in T-25 flasks. For parallel plate flow chamber studies, MS1 cells were seeded into 35-mm culture dishes and grown to confluency.
Flow cytometry analysis. The working dilutions of the ␤ 2-, ␤1-, ␣L-, and ␣M-antibodies, and ICAM-1, and VCAM-1 antibodies and their isotype controls were 1:320, 1:320, 1:80, 1:80, 1:80, and 1:80, respectively. Cultured WEHI and MS1 cell lines were harvested and washed in 10 ml of FACS buffer (PBS ϩ 1% FBS). An aliquot of 5 ϫ In vitro parallel plate flow chamber assays. Parallel plate flow chamber studies were performed as previously reported with slight modifications (21, 34) . Briefly, endothelial cell monolayers were stimulated with TNF-␣ (10 ng/ml) or PBS vehicle for 6 h. Monocytes or T cells were labeled with CMTPX CellTracker Red for 30 min at room temperature (Molecular Probes, Eugene, OR). The 200,000 cells/ml of either monocytes or T cells were perfused over endothelial monolayers using a parallel plate flow chamber maintained at 37°C (GlycoTech, Rockville, MD). In some experiments, 100 M of cLAB.L or control cyclic peptide was combined with labeled leukocytes and, subsequently, used for parallel plate flow studies. Cells were injected into the flow chamber in HBSS at a controlled physiological shear rate of 1.2 dynes/cm 2 using a programmable digital syringe pump (KD Scientific, New Hope, PA). Cells were viewed on a Nikon model TE2000 inverted microscope equipped with a Hamamatsu ORCA-ER digital charge-coupled device camera and viewed under epifluorescent illumination. Digital video of fluorescent cell signals were captured at a rate of 29 images per second over a 3-min period using Simple PCI software (Compix, Cranberry Township, PA). Digital images were analyzed to yield position measurements for every object in each frame. Position measurements were acquired and computed by the motion tracking analysis feature of Simple PCI software to determine leukocyte rolling velocity. Counts of rolling and firmly adherent cells were determined by computer analysis and confirmed by manual visual review of image sequences.
Statistical analyses. Data were statistically compared by using Prism 4.0 software (GraphPad). The number of firmly adherent and rolling cell data was compared by using a standard ANOVA with a Tukey's posttest to determine statistical differences between experimental groups. Numbers from firm adhesion and rolling cell data are reported as means Ϯ SD. Rolling velocity data from 1,200 cells per treatment group were compared by using a Kruskal-Wallis nonparametric ANOVA with a Dunnett's post test to determine statistical differences between experimental groups. Rolling velocity data are reported as a vertical box and whisker plot with a mean line and a relative frequency histogram distribution.
RESULTS

Identification of T cell and monocyte surface adhesion molecules.
Members of the ␤ 2 -and ␤ 1 -integrin families have been reported to be important for facilitating leukocyte-endothelial cell adhesion interactions (11, 20) . We determined surface adhesion molecule expression on established monocyte and T cell lines to identify possible integrins that could participate during leukocyte adhesion. Figure 1 shows surface expression of ␤ 1 -, ␤ 2 -, ␣ L -, and ␣ M -integrins between the two cell lines. (19) . In both experimental autoimmune diabetes models and clinical specimens, increased expression of ICAM-1 and VCAM-1 can be observed on islet microvascular endothelium (8, 10, 29) . Several different proinflammatory cytokines induce the expression of these adhesion molecules, such as TNF-␣ and IFN-␥, and have been reported in autoimmune diabetes models and from T1D patients (17, 25, 49) . Therefore, we examined induction of adhesion molecule expression in pancreatic islet microvascular endothelial cells in response to TNF-␣. Figure 2A shows that islet microvascular endothelial cells display constitutive surface expression of ICAM-1 that can be upregulated by stimulation with TNF-␣ (10 ng/ml). Moreover, Fig. 2B reveals minimal constitutive VCAM-1 surface expression that can also be induced by TNF-␣ (10 ng/ml). These data demonstrate that the in vitro islet microvascular endothelial cell adhesion molecule expression profile corresponds similarly to previous studies examining these molecules in clinical and animal model specimens.
Effect of cLAB.L on TNF-␣ mediated monocyte and T cell firm adhesion.
A recent study has shown that cyclic peptide antagonists against the ␣ L -integrin I domain can attenuate leukocyte-epithelial cell adhesive interactions under static conditions (52) . However, studies are lacking that examine whether these cyclic peptide antagonists interfere with leukocyte-microvascular endothelial cell interactions under hydro-dynamic flow conditions. Here we used the cLAB.L cyclic peptide to interfere with leukocyte-islet microvascular endothelial cell adhesion. This peptide is derived from the I-domain sequence of the ␣ L -integrin and has been shown to specifically bind to D1 of ICAM-1 (50). We quantified leukocyte firm adhesion with or without cyclic peptide treatment under basal or TNF-␣-stimulated conditions. Figure 3A shows that TNF-␣ stimulation increases monocyte adhesion that is not attenuated by cLAB.L peptide treatment. Conversely, TNF-␣ treatment increases T cell adhesion that is completely attenuated by cLAB.L treatment (Fig. 3B) . This inhibition is likely dependent on conversion of the ␣ L ␤ 2 -integrin to the "active" conformation, in that cLAB.L peptide treatment did not alter the number of adherent T cells under nonstimulated conditions. Figure 3 , C and D shows that control peptides did not affect monocyte or T cell adhesion in response to TNF-␣. These data demonstrate that the cLAB.L peptide specifically inhibits adhesion of T cells containing an active ␣ L ␤ 2 -integrin conformation.
Effect of cLAB.L on T cell rolling. Recent reports (12, 21) suggest that adhesion molecules involved in leukocyte firm adhesion can modulate various aspects of rolling. Moreover, the ␣ L ␤ 2 -integrin has been reported to facilitate leukocyte slow rolling that may subsequently influence firm adhesion (3, 38) . Figure 4 shows the effect of cLAB.L on the numbers and velocities of rolling T cells. Figure 4A demonstrates that cLAB.L treatment does not affect the number of rolling cells in response to TNF-␣. However, treatment with cLAB.L significantly increased the average rolling velocity. The mean rolling velocity for unstimulated conditions was 121.5 m/s, 88.7 m/s for TNF-␣ treatment, 107.0 m/s for TNF-␣ plus cLAB.L, and 82.3 m/s for TNF-␣ plus control peptide (Fig.  4B) . Figure 4C shows that TNF-␣ activation of islet microvascular endothelial cells increases the frequency of cells rolling at slower velocities compared with unstimulated endothelium. Interestingly, treatment with cLAB.L significantly decreased the frequency of cells rolling between 0 and 50 m/s. Together, these data clearly demonstrate that inhibition of ␣ Lintegrin I domain does not alter the ability of T cells to roll; rather, it increases the overall average rolling velocity and decreases the frequency of slow rolling cells.
DISCUSSION
T cell recruitment with subsequent islet ␤-cell destruction is a primary pathological feature of autoimmune diabetes. Recent advances in islet autoantibody detection have enabled prediction of T1D development in patients with susceptible haplotypes and suggest that therapeutic intervention may be feasible before the development of frank diabetes (35) . Whereas it is now possible to clinically diagnose autoimmune diabetes before symptoms occur, it is of little use if there are no interventions to interrupt immune cell attack on pancreatic islets. Recent interventional efforts have focused on inhibiting T cell receptor (TCR) engagement and subsequent T cell activation; however, other avenues for blocking immune cell recruitment and activation may provide additional benefit (13, 14) .
Studies (26, 28, 33, 37) from both animal models and clinical specimens implicate a role for cell adhesion molecules during the development of autoimmune diabetes. Increased leukocyte and endothelial cell adhesion molecule expression has been observed at initial diagnosis of T1D. Inhibition of some of these adhesion molecules can attenuate disease progression in the autoimmune diabetes-prone nonobese diabetic (NOD) mouse model (2, 26, 29, 30, 33, 37) . These observations clearly suggest that cell adhesion molecules participate in the pathogenesis of autoimmune diabetes, yet the specific molecular requirements and roles of these proteins are poorly understood.
Recent studies (42, 44) have advanced our understanding of how leukocyte integrins, such as ␣ L ␤ 2 -integrins, facilitate cell adhesion. Several molecular mechanisms have been identified that influence the conversion of ␣ L ␤ 2 -integrins from a resting to activated state, including divalent cation binding and conformational changes in protein structure (9, 22, 40) . Once activated, ␣ L ␤ 2 -integrins have been suggested to play a role in cell adhesion that may participate in cell rolling and during the transition to firm adhesion (23, 38) . However, the direct effect of competitive ligand antagonists with the ␣ L -integrin I domain during leukocyte-islet microvascular endothelial cell interactions has not been examined. In this study, we have examined the importance and mechanism of the ␣ L -integrin I domain in mediating T cell and monocyte adhesion to pancreatic islet microvascular endothelial cells.
cLAB.L peptide (cyclo1,12-PenITDGEATDSGC) was derived from 10 amino acid residues ( 237 Ile-246 Gly) of the ␣ Lintegrin I domain. The Pen1 and Cys12 residues were added to the NH 2 -and COOH-terminals of the 237 Ile-246 Gly sequence, respectively, to give a linear peptide PenITDGEATDSGC. The thiol groups in Pen1 and Cys12 were oxidized to make a disulfide bond to produce a cyclic peptide cLAB.L. The cLAB.L peptide has been shown to bind to domain 1 (D1) of ICAM-1 and inhibit both homotypic and mixed lymphocyte reactions, as well as heterotypic T-cell adhesion to epithelial cell monolayers (46, 52, 53) . The conformation of cLAB.L as determined by NMR and molecular dynamics simulations shows that cLAB.L peptide has a stable ␤IIЈ-turn at Asp4-Gly5-Glu6-Ala7 and a ␤IЈ-turn at Pen1-Ile2-Thr3-Asp4 (50) . It is interesting to find that the X-ray structure of the I domain at 239 Asp-Gly-Glu-242 Ala has a ␤-turn conformation, suggesting that the cyclic formation of cLAB.L maintains the conformation of these residues. In addition, docking studies (50) of cLAB.L peptide onto D1 of ICAM-1 indicate that Ile2 to Thr8 residues of cLAB.L peptide interact with the F and C strands of ICAM-1. These results suggest that cLAB.L peptide binds to F and C stands of D1 of ICAM-1, thereby blocking the interaction between ␣ L -integrin I domain and ICAM-1.
Our data clearly demonstrate that ␣ L -integrin I domainligand interactions play a dominant role in mediating T cell adhesion to islet microvascular endothelium as demonstrated by cLAB.L peptide. Importantly, other cell adhesion molecules were found on both cell types, specifically VCAM-1 and VLA-4, which were not able to mediate firm adhesion after inhibition of ␣ L -integrin with the cLAB.L peptide. Our data also indicate that the cLAB.L peptide specifically blocks ␣ L ␤ 2 -antigen-mediated adhesion, because it did not affect adhesion of monocytes that only express ␣ M ␤ 2-(Mac-1) and ␤ 1 -integrin (VLA-4). Because cLAB.L is derived from the I-domain of ␣ L , these data indicate that this region of the I domain is important for ␣ L ␤ 2 -integrin-mediated leukocyte-endothelial cell adhesion, and further demonstrate that this segment of the ␣ Lintegrin I domain selectively differentiates ␣ L -vs. ␣ M -integrin binding to ICAM-1. Taken together, these data demonstrate for the first time that the ␣ L -integrin I domain is critical for T cell adhesion to islet microvascular endothelium and that this adhesion can be prevented by peptide antagonists that compete for the ␣ L -integrin I domain ligand.
Recent studies (12, 21) have shown that ␣ L ␤ 2 -integrin may influence the nature of leukocyte rolling. Whereas the selectin proteins are the primary mediators of immune cell capture and rolling, studies have shown that ␤ 2 -integrins and their ligands, such as ICAM-1, clearly modulate cell rolling. Sigal et al. (41) has shown that ␣ L ␤ 2 -integrins can support rolling under physiological shear stress that is dependent on ICAM-1 surface density. Another study, by Dunne et al. (3) examined leukocyte rolling parameters in ␤ 2 -, ␣ L -, or ␣ M -integrin null mice and found increased average rolling velocities in ␣ L -and ␣ Mmutants, along with a higher increase in rolling velocities of ␤ 2 -null mutants. An important finding of this study was that leukocyte adhesion efficiency was similarly decreased in ␣ Land ␤ 2 -mutants, but only slightly attenuated in ␣ M -mutants. These results further indicate that ␣ L ␤ 2 -antigen is important for the conversion of leukocyte rolling to firm adhesion. Interestingly, our data demonstrate that competitive inhibition for ␣ L -integrin I domain ligand significantly increases average leukocyte rolling velocities. Inhibition of ␣ L -integrin I domain binding primarily affected slow rolling velocities (0 -50 m/s), which may impede the transition of leukocyte rolling to firm adhesion. Together with previous studies, our data strongly suggest an important role for ␣ L -integrin I domain in facilitating T cell slow rolling and transition to firm adhesion on islet microvascular endothelium.
Much effort is currently focused on identifying small molecule ␣ L -antagonists with the anticipation that these compounds will provide new avenues for therapeutic intervention in several chronic inflammatory diseases, including autoimmune diabetes (1, 39, 48) . Here we have examined the utility of cyclic peptide antagonists against ␣ L -integrin I domain in preventing T cell-islet endothelial cell interactions. Our data show that peptide antagonists competing for ␣ L -integrin I domain ligand specifically inhibit T cell adhesion, enabling other leukocyte adhesion. These data are the first to describe the effect of ␣ L -integrin I domain antagonists in a physiological leukocyte-islet microvascular endothelial cell hydrodynamic flow model. Therapeutic interventions using this type of approach may prove useful in attenuating insulitis and ␤-cell destruction observed in T1D. 
